Session Item

Since the early ´90ies adjuvant chemotherapy – mainly cisplatin with or without 5-FU – hast been used for certain indications in combination with postoperative radiotherapy (PORT) after surgery for oral cavity cancer.
The presentation will discuss why cisplatin is valuable in combination with radiotherapy and the present well-established indications: positive margins, extracapsular extension and TNM classificationT3-4 and/or N2-3. The actual evidence for the more relative indications will also be revisited, like perineural or lympho-vascular invasion, depth of tumor invasion and positive resection margins followed by additional resection. Recently, the discussion of what is actually positive margins and ECE has been revitalized and together with the importance of p16/HPV status this will be debated. Furthermore, the evidence for doses and types of drugs is discussed and finally, a list of burning research questions for the future is suggested.